Anlotinib‑induced acute myocardial infarction: A case report and literature review

Liu,Guihong; Chen,Tao; Ding,Zhenyu

doi:10.3892/etm.2020.9041

Anlotinib‑induced acute myocardial infarction: A case report and literature review

Authors:
- Guihong Liu
- Tao Chen
- Zhenyu Ding
View Affiliations

Affiliations: Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Cardiology Department, Chengdu No. 7 People's Hospital, Chengdu Tumor Hospital, Chengdu, Sichuan 610041, P.R. China
Published online on: July 24, 2020 https://doi.org/10.3892/etm.2020.9041
Pages: 3203-3207
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anlotinib hydrochloride is a multi‑target tyrosine kinase inhibitor, which has been recently approved for the treatment of advanced non‑small cell lung cancer in China. One of its mechanisms of action is the inhibition of angiogenesis and it is similar to other anti‑angiogenesis drugs, as it has cardiovascular toxicity, which may damage vascular endothelial cells and result in hypertension and hyperlipidemia. All of the aforementioned factors are considered risk factors for coronary heart disease; however, the risk of developing acute myocardial infarction (AMI) has not been assessed by any previous clinical trials and subsequent research. The present case study, to the best of our knowledge, was the first to report on a patient who developed hypertension, hyperlipidemia and angina pectoris, and eventually experienced AMI, following treatment with anlotinib. This indicates that patients receiving anlotinib may require further observation and monitoring during use.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
2	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016.PubMed/NCBI View Article : Google Scholar
3	Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
4	Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 9(105)2016.PubMed/NCBI View Article : Google Scholar
5	Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, et al: Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 118:654–661. 2018.PubMed/NCBI View Article : Google Scholar
6	Rami-Porta R, Bolejaek V, Giroux DJ, Chansky K, Crowley J, Asamura H and Goldstraw P: International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASLC lung cancer staging project: The new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 9:1618–1624. 2014.PubMed/NCBI View Article : Google Scholar
7	Anderson JL and Morrow DA: Acute myocardial infarction. N Engl J Med. 376:2053–2064. 2017.PubMed/NCBI View Article : Google Scholar
8	Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R and Hassoun H: High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol. 29:3466–3473. 2011.PubMed/NCBI View Article : Google Scholar
9	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.PubMed/NCBI View Article : Google Scholar
10	Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC and Donehower RC: Cardiac disturbances during the administration of taxol. J Clin Oncol. 9:1704–1712. 1991.PubMed/NCBI View Article : Google Scholar
11	Ali RM, Abdul Kader MASK, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, Zuhdi ASM, Nuruddin AA, Schnorr B and Scheller B: Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc Interv. 12:558–566. 2019.PubMed/NCBI View Article : Google Scholar
12	Dasanu CA: Gemcitabine: Vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 7:703–716. 2008.PubMed/NCBI View Article : Google Scholar
13	Gu L, Zhong D, Yu T, Tang P, Meng F and Qin Q: Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer. Thorac Cancer. 10:226–233. 2019.PubMed/NCBI View Article : Google Scholar
14	Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 368:987–998. 2013.PubMed/NCBI View Article : Google Scholar
15	Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al: 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed underthe auspices of the ESC committee for practice guidelines: The task force for cancertreatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J. 37:2768–2801. 2016.PubMed/NCBI View Article : Google Scholar
16	Lee CC, Zheng H, Soon YY, Foo LL, Koh WY, Leong CN, Vellayappan B, Tey JCS and Tham IWK: Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy. Lung Cancer. 120:54–59. 2018.PubMed/NCBI View Article : Google Scholar
17	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971.PubMed/NCBI View Article : Google Scholar
18	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.PubMed/NCBI View Article : Google Scholar
19	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.PubMed/NCBI View Article : Google Scholar
20	Baluk P, Hashizume H and McDonald DM: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 15:102–111. 2005.PubMed/NCBI View Article : Google Scholar
21	Claesson-Welsh L: Blood vessels as targets in tumor therapy. Ups J Med Sci. 117:178–186. 2012.PubMed/NCBI View Article : Google Scholar
22	Lugano R, Ramachandran M and Dimberg A: Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell Mol Life Sci. 77:1745–1770. 2020.PubMed/NCBI View Article : Google Scholar
23	Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P and Amir E: Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev. 53:120–127. 2017.PubMed/NCBI View Article : Google Scholar
24	Ivy SP, Wick JY and Kaufman BM: An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 6:569–579. 2009.PubMed/NCBI View Article : Google Scholar
25	Choueiri TK, Schutz FA, Je Y, Rosenberg JE and Bellmunt J: Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol. 28:2280–2285. 2010.PubMed/NCBI View Article : Google Scholar
26	Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH and Johnson DH: Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 28:949–954. 2010.PubMed/NCBI View Article : Google Scholar
27	Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, et al: Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): A multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 20:1109–1123. 2019.PubMed/NCBI View Article : Google Scholar
28	Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, et al: China national medical products administration approval summary: Anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond). 39(36)2019.PubMed/NCBI View Article : Google Scholar